[Level of evidence for therapeutic drug monitoring of everolimus].

Clicks: 274
ID: 72785
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Everolimus has proven efficacy for prevention of rejection in adult de novo renal and cardiac transplant recipient in combination with ciclosporine and corticosteroids. Therapeutic drug monitoring (TDM) with target trough concentration (C0) value from 3 to 8 µg/L has been proposed. Through a systematic review of the literature, this work explored a level of recommendation for this TDM. Everolimus exhibits both wide interindividual pharmacokinetic variability and poor relationship between dose and exposure. A good relationship has been reported between C0 values and global exposure to the drug (i.e. AUC). Although C0 > 3 µg/L has been associated with a decreased incidence of rejection, the upper limit of 8 µg/L has never been formally validated. No clinical trial testing other exposure indices or comparing efficacy and/or toxicity of everolimus therapy with and without TDM has been published so far. Consequently the level of recommendation for everolimus monitoring is "recommended".
Reference Key
goirandleveltherapie Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Goirand, Françoise;Royer, Bernard;Hulin, Anne;Saint-Marcoux, Franck;, ;
Journal therapie
Year Year not found
DOI DOI not found
URL URL not found
Keywords
therapeutic drug monitoring transplantation kidney pharmacokinetics liver tacrolimus algorithm mycophenolic acid dose ciclosporin equation immunosuppressive drugs

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.